| 摘要 |
The present solution relates to crystalline forms of (3R)-3-cyclopentyl-3-[4-(7H-pyrolo[2,3-d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile salts of Formula I, wherein HX represents at least one acid component, preferably a hydrohalic acid, more preferably HX is selected from the group consisting of hydrofluoric acid, hydrochloric acid, hydrobromic acid and hydriodic acid or even more preferably HX is selected from the group consisting of hydrobromic acid or hydrochloric acid. Further solution relates to a process for the preparation thereof, as well as use thereof in pharmaceutically acceptable compositions. Use of said crystalline forms of ruxolitinib and manufactured salts in the preparation of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile in the free form or in the form of any pharmaceutically acceptable salt thereof is also part of this invention. |
